| scholarly article | Q13442814 |
| P356 | DOI | 10.2174/187152309789151977 |
| P953 | full work available at URL | https://europepmc.org/articles/pmc2947383?pdf=render |
| https://europepmc.org/articles/PMC2947383 | ||
| https://europepmc.org/articles/PMC2947383?pdf=render | ||
| http://eurekaselect.com/article/download/70087 | ||
| https://doi.org/10.2174/187152309789151977 | ||
| P932 | PMC publication ID | 2947383 |
| P698 | PubMed publication ID | 20890386 |
| P5875 | ResearchGate publication ID | 47300901 |
| P2093 | author name string | Elaine O. Petrof | |
| P2860 | cites work | Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG | Q78144305 |
| Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs | Q80463718 | ||
| Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis | Q24529831 | ||
| Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells | Q24545538 | ||
| Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa | Q24548845 | ||
| Antimicrobial substance from a human Lactobacillus strain | Q24676914 | ||
| Potential uses of probiotics in clinical practice | Q24681377 | ||
| Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 | ||
| Host-bacterial mutualism in the human intestine | Q27861037 | ||
| Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial | Q28142345 | ||
| Systematics of the Lactobacillus population on rat intestinal mucosa with special reference to Lactobacillus reuteri | Q28211822 | ||
| Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo | Q28235409 | ||
| Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration | Q28250255 | ||
| A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease | Q28254686 | ||
| Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis | Q28258829 | ||
| Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii | Q28276207 | ||
| Probiotics for prevention of antibiotic-associated diarrhea | Q28283304 | ||
| Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells | Q28290485 | ||
| Development of intestinal lactobacilli in normal piglets | Q28291704 | ||
| A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children | Q28302728 | ||
| Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children | Q29028534 | ||
| Ecological and evolutionary forces shaping microbial diversity in the human intestine | Q29547586 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Phylogenetic analysis of cecal microbiota in chicken by the use of 16S rDNA clone libraries | Q30840362 | ||
| Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research | Q33341412 | ||
| The search for disease-associated compositional shifts in bowel bacterial communities of humans | Q33368533 | ||
| Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells | Q33554139 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study | Q33878836 | ||
| Recommendations for probiotic use--2008. | Q34012172 | ||
| Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. | Q34415570 | ||
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
| Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease | Q34517039 | ||
| Saccharomyces cerevisiae fungemia: an emerging infectious disease | Q34557580 | ||
| Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function | Q34587671 | ||
| How host-microbial interactions shape the nutrient environment of the mammalian intestine | Q34675981 | ||
| Clinical use of E. coli Nissle 1917 in inflammatory bowel disease | Q34744012 | ||
| Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial | Q34750864 | ||
| Bacteriocins: evolution, ecology, and application | Q34762780 | ||
| Exploring the relationships between intestinal microflora and inflammatory conditions of the human bowel and spine | Q35007781 | ||
| Safety of probiotics that contain lactobacilli or bifidobacteria | Q35081764 | ||
| Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease | Q35431790 | ||
| Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. | Q35532152 | ||
| Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans | Q35542625 | ||
| Outbreak of Saccharomyces cerevisiae Subtype boulardii Fungemia in Patients Neighboring Those Treated with a Probiotic Preparation of the Organism | Q35578814 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. | Q35778159 | ||
| Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics | Q35787456 | ||
| The importance of guidelines in the development and application of probiotics. | Q36002824 | ||
| The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. | Q36220431 | ||
| Treatment of recurrent Clostridium difficile-associated disease | Q36304037 | ||
| Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy | Q36481501 | ||
| Review: probiotics are effective for prevention of antibiotic-associated diarrhea and treatment of Clostridium difficile disease. | Q36582603 | ||
| Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. | Q36807314 | ||
| Clinical recognition and diagnosis of Clostridium difficile infection | Q37051294 | ||
| The role of microbiota in infectious disease | Q37086530 | ||
| Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism | Q37122645 | ||
| Bacteria-free solution derived from Lactobacillus plantarum inhibits multiple NF-kappaB pathways and inhibits proteasome function | Q37356352 | ||
| Defensins and inflammation: the role of defensins in inflammatory bowel disease | Q37392351 | ||
| Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice | Q39519683 | ||
| Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells | Q39536940 | ||
| Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling | Q40004010 | ||
| NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. | Q40017434 | ||
| Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells | Q40060675 | ||
| Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun | Q40100857 | ||
| Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair | Q40211588 | ||
| Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways | Q40264330 | ||
| Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells | Q40348113 | ||
| Functional modulation of enterocytes by gram-positive and gram-negative microorganisms | Q40580514 | ||
| Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial | Q40651311 | ||
| Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis | Q40685749 | ||
| Probiotic bacteria enhance murine and human intestinal epithelial barrier function | Q40783633 | ||
| Heat-shock protein 72 protects against oxidant-induced injury of barrier function of human colonic epithelial Caco2/bbe cells | Q40945966 | ||
| Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. | Q41761349 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Identification and antibiotic susceptibility of bacterial isolates from probiotic products | Q44210873 | ||
| Disposition kinetics of Saccharomyces boulardii in man and rat. | Q44265947 | ||
| Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition | Q45134589 | ||
| Survival of Lactobacillus species (strain GG) in human gastrointestinal tract | Q46653370 | ||
| DNA from probiotic bacteria modulates murine and human epithelial and immune function | Q47635337 | ||
| Probiotic foods and drugs: impact of US regulatory status on design of clinical trials | Q47722602 | ||
| Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. | Q54511436 | ||
| Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. | Q55036595 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice | Q59120727 | ||
| Is Lactobacillus GG Helpful in Children With Crohn’s Disease? Results of a Preliminary, Open-Label Study | Q63285887 | ||
| Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii | Q68841505 | ||
| Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study | Q69182379 | ||
| Fecal recovery following oral administration of Lactobacillus strain GG (ATCC 53103) in gelatine capsules to healthy volunteers | Q71713394 | ||
| Lactic Acid Bacteria in the Treatment of Acute Rotavirus Gastroenteritis | Q71871032 | ||
| Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats | Q72638574 | ||
| The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii | Q73118857 | ||
| Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children | Q73325307 | ||
| Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants | Q73592019 | ||
| Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis | Q73837821 | ||
| [Mutaflor and its medical significance.] | Q75633094 | ||
| Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells | Q77373909 | ||
| Deficiencies in microbiological quality and labelling of probiotic supplements | Q77655377 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | probiotics | Q1816730 |
| gastrointestinal system disease | Q2300099 | ||
| P304 | page(s) | 260-269 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry | Q15765055 |
| P1476 | title | Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science | |
| P478 | volume | 8 |
| Q34387493 | Anti-inflammatory properties of Streptococcus salivarius, a commensal bacterium of the oral cavity and digestive tract. |
| Q39263514 | Dietary metabolites derived from gut microbiota: critical modulators of epigenetic changes in mammals |
| Q38647859 | Effect of EPEC endotoxin and bifidobacteria on intestinal barrier function through modulation of toll-like receptor 2 and toll-like receptor 4 expression in intestinal epithelial cell-18. |
| Q35413104 | Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial |
| Q40899414 | In vivo gut transcriptome responses to Lactobacillus rhamnosus GG and Lactobacillus acidophilus in neonatal gnotobiotic piglets |
| Q30416554 | Lactic acid production by Streptococcus thermophilus alters Clostridium difficile infection and in vitro Toxin A production |
| Q45795481 | Lactobacillus rhamnosus protects human colonic muscle from pathogen lipopolysaccharide-induced damage. |
| Q37570919 | Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study |
| Q89476653 | Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases |
| Q43017439 | Potential probiotic thermophiles isolated from mice after compost ingestion |
| Q34364074 | Probiotics for the treatment of Clostridium difficile associated disease |
| Q33736314 | Protective effect of Laminaria japonica with probiotics on murine colitis |
| Q33694127 | Screening of Lactobacillus spp. for the prevention of Pseudomonas aeruginosa pulmonary infections |
| Q54408784 | Simultaneous Amelioratation of Colitis and Liver Injury in Mice by Bifidobacterium longum LC67 and Lactobacillus plantarum LC27. |
| Q35054819 | Small molecule immunomodulins from cultures of the human microbiome member Lactobacillus plantarum |
| Q38077632 | Sources, isolation, characterisation and evaluation of probiotics |
| Q40092400 | The Effect of a Yeast Probiotic on Acute Diarrhea in Children. |
| Q40064554 | The Role of Probiotics in the Treatment of Dysentery: a Randomized Double-Blind Clinical Trial. |
| Q84582157 | The effect of immobilization of probiotic Lactobacillus reuteri DPC16 in sub-100 μm microcapsule on food-borne pathogens |
| Q44249573 | Who will win the race in childrens' oral cavities? Streptococcus mutans or beneficial lactic acid bacteria? |
Search more.